<DOC>
	<DOCNO>NCT02131584</DOCNO>
	<brief_summary>The goal clinical research study learn Jakafi ( ruxolitinib ) help control fatigue symptom patient CLL need treatment cancer . Researchers also want learn ruxolitinib decrease size enlarge lymph node and/or low number CLL cell blood .</brief_summary>
	<brief_title>Administration Jakafi ( Ruxolitinib ) Symptom Control Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take ruxolitinib pill 2 time day , 12 hour apart . If miss dose , take extra dose . Instead , take next dose time . If vomit dose within 30 minute take , take extra dose make . If vomit 30 minute pass since take ruxolitinib , take extra dose . Instead , take next dose time . If need , doctor may raise low dose ruxolitinib , base disease respond drug experience severe side effect . Study Visits : At 2 week 3 month first study drug dose : - Blood ( 1 teaspoon ) drawn cytokine test . - You fill symptom questionnaire clinic visit . About every 1-2 month : - You physical exam . - Blood ( 1 teaspoon ) drawn routine test . If convenient , study test procedures do home doctor 's office . Length Treatment : You may receive study drug 2 year . At point , may allow continue take study drug long sponsor provide drug doctor think best interest . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . This investigational study . Ruxolitinib FDA approve commercially available treatment myelofibrosis ( MF ) . Giving ruxolitinib patient CLL investigational . The study doctor explain study drug design work . Up 60 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>1 . Subjects able understand sign inform consent document . 2 . Subjects 18 year age old . 3 . Subjects must diagnose CLL meet IWCLL criterion treatment . 4 . Patients may previously treat previously untreated . 5 . Symptomatic patient BFI symptom scale 2 point great . 6 . Subjects hemoglobin value Screening visit equal great 12.0 g/dL . 7 . Subjects platelet count least 75 x10^9/L screen visit . 8 . Subjects absolute neutrophil count ( ANC ) equal high 0.5 x109/L screen visit . 9 . Subjects must discontinue drug use treat CLL later Day 30 . 10 . Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 2 . 1 . Females pregnant currently breastfeed . 2 . Subjects childbearing potential unwilling take appropriate precaution ( throughout study screening , include 30 day discontinuation study drug ) avoid become pregnant fathering child . Females nonchildbearing potential define woman ( ) equal great 55 year age history amenorrhea 1 year , OR ( b ) surgically sterile least 3 month . For female childbearing potential , male , appropriate precaution least 99 % effective preventing occurrence pregnancy . These method communicate subject understand confirm : •Complete abstinence sexual intercourse •Double barrier method •Condom spermicide conjunction use intrauterine device ( IUD ) •condom spermicide conjunction use diaphragm •Oral , injectable , implanted contraceptive •Tubal ligation vasectomy ( surgical sterilization ) 3 . Subjects recent history inadequate bone marrow reserve demonstrate previous transfusion except acute blood loss ( e.g . surgery ) month prior screen . 4 . Subjects inadequate liver renal function screen baseline visit : • Alanine aminotransferase ( ALT ) &gt; 2.5x ULN . • Modification Diet Renal Disease ( MDRD ) calculate GFR &lt; 30 mL/min 5 . Subjects active uncontrolled infection HIV positive ( Subjects acute infection require treatment delay screening/enrollment course therapy complete event consider control ) . 6 . Subjects invasive malignancy previous 2 year except treat basal squamous carcinoma skin completely resect intraepithelial carcinoma cervix completely resect papillary thyroid follicular thyroid cancer . Other completely resect cancer great 2 year may consider review PI . 7 . Subjects clinically significant uncontrolled cardiac disease . 8 . Subjects treat concurrently prohibit medication , include investigational medication , rifampin , St. John 's wort , potent CYP3A4 inhibitor ( exclude ketoconazole ) unless continuation medication determine investigator best interest patient . 9 . Subjects previously receive JAK inhibitor therapy . 10 . Subjects active alcohol drug addiction would interfere ability comply study requirement . 11 . Subjects concurrent condition , Investigator 's opinion , would jeopardize safety subject compliance protocol . 12 . Subjects unknown transfusion history least 12 week prior screen . 13 . Subjects unable complete symptom diary . 14 . Subjects need conventional therapy course study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Fatigue</keyword>
	<keyword>Brief Fatigue Inventory</keyword>
	<keyword>BFI</keyword>
	<keyword>Questionnaires</keyword>
	<keyword>Surveys</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>Jakafi</keyword>
	<keyword>INCB018424</keyword>
	<keyword>INC424</keyword>
</DOC>